Vaccine Pioneer Joins Inovio Biomedical`s Scientific Advisory Board

Renowned Vaccine Scientist Dr. Stanley Plotkin to Help Guide Inovio`s Efforts to
Develop Preventive and Therapeutic DNA Vaccines
SAN DIEGO--(Business Wire)--
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design,
development and delivery, announced today that Stanley A. Plotkin, MD, has
agreed to join the company`s scientific advisory board.

Dr. Plotkin developed the rubella vaccine now used worldwide and has worked
extensively on the development and application of other vaccines including
polio, rabies, varicella, rotavirus and cytomegalovirus. He is Emeritus
Professor, Wistar Institute and the University of Pennsylvania, and Executive
Advisor to the CEO of Sanofi Pasteur.

Over the course of his career he has served as senior assistant surgeon with the
Epidemic Intelligence Service, U.S. Public Health Service; director of the
Division of Infectious Diseases at Children`s Hospital of Philadelphia;
associate chairman of the Department of Pediatrics, University of Pennsylvania;
and medical and scientific director of Aventis Pasteur.

Dr. Plotkin`s professional awards include the Sabin Foundation Medal (2002); the
French Legion Medal of Honor (1998); the Clinical Virology Award, Pan American
Group for Rapid Viral Diagnosis (1995); the Distinguished Physician Award,
Pediatric Infectious Disease Society (1993); and the Bruce Medal of the American
College of Physicians (1987).

Dr. J. Joseph Kim, Inovio`s CEO, stated, "Dr. Plotkin is an internationally
renowned virologist who has made significant contributions to the goal of
conquering diseases with vaccines. We are honored to have Dr Plotkin join our
distinguished panel of scientific advisors, who are committed to helping guide
Inovio`s development of DNA vaccines, a potentially vital new generation of
vaccines targeting cancers and chronic infectious diseases."

Dr. Plotkin joins Dr. David B. Weiner and Dr. Robert S. Langer on Inovio's
Scientific Advisory Board. Dr. Weiner is Chairman of the Scientific Advisory
Board and is a professor of the Department of Pathology & Laboratory Medicine,
University of Pennsylvania. Dr. Weiner is considered to be a pioneer of the
field of DNA vaccines. Dr. Langer, Germeshausen Professor of Chemical and
Biomedical Engineering at the Massachusetts Institute of Technology, is a
renowned scientist with numerous distinguished awards. Drs. Weiner and Langer
have both advised organizations such as the FDA and multiple life sciences
companies. Both Drs. Weiner and Langer have served as founding members of the
scientific advisory board of VGX Pharmaceuticals, which merged with Inovio
Biomedical on June 1, 2009.

About Inovio Biomedical Corporation

Inovio Biomedical is engaged in the design, development, and delivery of a new
generation of vaccines, called DNA vaccines, focused on cancers and infectious
diseases. The company`s SynCon technology enables the design of DNA-based
vaccines capable of providing cross-protection against evolving, unmatched
strains of pathogens such as influenza. Inovio`s proprietary electroporation DNA
delivery technology uses brief, controlled electrical pulses to increase
cellular DNA vaccine uptake. Initial human data has shown this method can safely
and significantly increase gene expression and immune responses. Inovio`s
clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An
IND has been filed for an avian influenza vaccine. Partners and collaborators
include Merck, Tripep, University of Southampton, University of Pennsylvania,
and HIV Vaccines Trial Network. Inovio`s product candidates and technologies are
protected by an extensive global intellectual property portfolio. More
information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our
plans to develop electroporation-based drug and gene delivery technologies and
DNA vaccines. Actual events or results may differ from the expectations set
forth herein as a result of a number of factors, including uncertainties
inherent in clinical trials and product development programs (including, but not
limited to, the fact that pre-clinical and clinical results referenced in this
release may not be indicative of results achievable in other trials or for other
indications and that results from one study may not necessarily be reflected or
supported by the results of other similar studies), the availability of funding
to support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or develop viable
DNA vaccines, the availability or potential availability of alternative
therapies or treatments for the conditions targeted by the parties or their
collaborators, including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the parties and their
collaborators hope to develop, evaluation of potential opportunities, issues
involving patents and whether they or licenses to them will provide the parties
with meaningful protection from others using the covered technologies, whether
such proprietary rights are enforceable or defensible or infringe or allegedly
infringe on rights of others or can withstand claims of invalidity and whether
the combined company can finance or devote other significant resources that may
be necessary to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the companies` combined technology by potential
corporate or other partners or collaborators, capital market conditions, our
ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of
government healthcare proposals, our ability to maintain listing of our common
stock under the rules and regulations of the NYSE Amex and other factors set
forth in our Annual Report on Form 10-K for the year ended December 31, 2008,
our Form 10-Q for the three months ended March 31, 2009, and other regulatory
filings from time to time, including our current report on Form 8-K reporting
the closing of the merger transaction with VGX Pharmaceuticals, Inc. There can
be no assurance that any product in Inovio`s pipeline will be successfully
developed or manufactured, that final results of clinical studies will be
supportive of regulatory approvals required to market licensed products, or that
any of the forward-looking information provided herein will be proven accurate.

Investors:
Inovio Biomedical
Bernie Hertel, 858-410-3101
or
Media:
Richardson & Associates
Jeff Richardson, 805-491-8313

Copyright Business Wire 2009